K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Exclusion Criteria

• •Previous treatment with immune checkpoint inhibitor (Anti-PD1, Anti-PDL1, Anti-CTLA4 etc.)
• •Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
• •Prior organ transplantation, including allogeneic stem cell transplantation
• •Significant acute or chronic infections
• •Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:
• •All subjects with brain metastases, except those meeting the following criteria:
• •Subjects with clinically significant (i.e., active) cardiovascular medical history: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication
• •Unresolved toxicity of Grade \>1 attributed to any prior therapies (excluding alopecia, skin pigmentation and anemia).
• •Pregnancy or lactation
• •Interstitial lung disease
• •Known alcohol or drug abuse
• •All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment
• •Any psychiatric condition that would prohibit the understanding or rendering of informed consent
• •Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines